References
- SnyderRGlasserDAntibiotic therapy for ocular infectionWest J Med199416165795847856158
- HughesLMauriceDA fresh look at iontophoresisArch Ophthalmol198410212182518296508622
- HovdingGAcute bacterial conjunctivitisActa Ophthalmol200886151717970823
- RosePManagement strategies for acute infective conjunctivitis in primary care: a systematic reviewExpert Opin Pharmacother20078121903192117696792
- AllanBDDartJKStrategies for the management of microbial keratitisBr J Ophthalmol19957987777867547792
- BourcierTThomasFBorderieVChaumeilCLarocheLBacterial keratitis: predisposing factors, clinical and microbiological review of 300 casesBr J Ophthalmol200387783483812812878
- GreenMApelAStapletonFRisk factors and causative organisms in microbial keratitisCornea2008271222718245962
- GreenMDApelAJNaduvilathTStapletonFJClinical outcomes of keratitisClin Experiment Ophthalmol200735542142617651246
- CalleganMCGilmoreMSGregoryMBacterial endophthalmitis: therapeutic challenges and host-pathogen interactionsProg Retin Eye Res200726218920317236804
- DeCroosFCAfshariNAPerioperative antibiotics and anti-inflammatory agents in cataract surgeryCurr Opin Ophthalmol2008191222618090893
- KowalskiRPDhaliwalDKOcular bacterial infections: current and future treatment optionsExpert Rev Anti Infect Ther20053113113915757463
- Tovilla-CanalesJLNavaATovilla y PomarJLOrbital and periorbital infectionsCurr Opin Ophthalmol200112533534111588494
- CampolattaroBNLuederGTTychsenLSpectrum of pediatric dacryocystitis: medical and surgical management of 54 casesJ Pediatr Ophthalmol Strabismus19973431431539168418
- Summary benchmarks for preferred practice pattern guidelinesSan Francisco, CAAmerican Academy of Ophthalmology2007
- American Academy of Ophthalmology Cornea and External Disease PanelPreferred practice pattern: conjunctivitisSan Francisco, CAAmerican Academy of Ophthalmology2003
- American Academy of Ophthalmology Cornea and External Disease PanelPreferred practice pattern: bacterial keratitisSan Francisco, CAAmerican Academy of Ophthalmology2005
- DartJKRadfordCFMinassianDVermaSStapletonFRisk factors for microbial keratitis with contemporary contact lenses: a case-control studyOphthalmology2008115101647165418597850
- DonahueSPKhouryJMKowalskiRPCommon ocular infections. A prescriber’s guideDrugs19965245265408891465
- BartlettJDOphthalmic Drug Facts20th edSt Louis, MOWolters Kluwer Health2009
- MulliganMJCobbsCGBacteriostatic versus bactericidal activityInfect Dis Clin North Am1989333893982671128
- FraunfelderFCorneal toxicity from topical ocular and systemic medicationsCornea200625101133113817172885
- SchlechBABlondeauJFuture of ophthalmic anti-infective therapy and the role of moxifloxacin ophthalmic solution 0.5% (VIGAMOX)Surv Ophthalmol200550Suppl 1S64S6716257312
- KowalskiRPDhaliwalDKKarenchakLMGatifloxacin and moxifloxacin: an in vitro susceptibility comparison to levofloxacin, ciprofloxacin, and ofloxacin using bacterial keratitis isolatesAm J Ophthalmol2003136350050512967804
- StrattonCWDead bugs don’t mutate: susceptibility issues in the emergence of bacterial resistanceEmerg Infect Dis200391101612533275
- AsbellPASahmDFNationwide antimicrobial susceptibility surveillance of ocular isolates: results of Ocular TRUSTPresented at the American Society of Cataract and Refractive Surgery Annual Meeting2007 Apr 22–May 2San Diego, CAAbstract #P-114.
- AsbellPAColbyKADengSOcular TRUST: nationwide antimicrobial susceptibility patterns in ocular isolatesAm J Ophthalmol2008145695195818374299
- AsbellPASahmDFShawMDraghiDCBrownNPIncreasing prevalence of methicillin resistance in serious ocular infections caused by Staphylococcus aureus in the United States: 2000 to 2005J Cataract Refract Surg200834581481818471638
- HwangDGThe top four errors in prescribing antibioticsCataract Refract Surg Today220055558
- BlondeauJMHansenGMetzlerKHedlinPThe role of PK/PD parameters to avoid selection and increase of resistance: mutant prevention concentrationJ Chemother200416Suppl 311915334827
- BartlettJDJaanusSClinical Ocular PharmacologySt. Louis, MOButterworth Heinemann Elsevier2008
- CavuotoKZutshiDKarpCLMillerDFeuerWUpdate on bacterial conjunctivitis in South FloridaOphthalmology20081151515617572497
- SheikhAHurwitzBAntibiotics versus placebo for acute bacterial conjunctivitisCochrane Database Syst Rev20062CD00121116625540
- PachigollaGBlomquistPCavanaghHDMicrobial keratitis pathogens and antibiotic susceptibilities: a 5-year review of cases at an urban county hospital in north TexasEye Contact Lens2007331454917224678
- KeayLEdwardsKNaduvilathTMicrobial keratitis predisposing factors and morbidityOphthalmology2006113110911616360210
- Ciloxan [package insert]Fort Worth, TXAlcon Laboratories, Inc31998
- Ocuflox [package insert]Irvine, CAAllergan Inc71993
- Iquix [package insert]Jacksonville, FLVistakon Pharmaceuticals LLC42007
- BhavsarARIpMSGlassmanARThe risk of endophthalmitis following intravitreal triamcinolone injection in the DRCRnet and SCORE clinical trialsAm J Ophthalmol2007144345445617765429
- JonasJBIntravitreal triamcinolone acetonide: a change in a paradigmOphthalmic Res200638421824516763379
- TabanMBehrensANewcombRAcute endophthalmitis following cataract surgery: a systematic review of the literatureArch Ophthalmol2005123561362015883279
- WestESBehrensAMcDonnellPJTielschJMScheinODThe incidence of endophthalmitis after cataract surgery among the US Medicare population increased between 1994 and 2001Ophthalmology200511281388139415953637
- JohnsonMDoftBKelseySThe Endophthalmitis Vitrectomy Study: relationship between clinical presentation and microbiologic spectrumOphthalmology199710422612729052630
- JagerRAielloLPatelSCunninghamEJRisks of intravitreous injection: a comprehensive reviewRetina200424567669815492621
- JonasJBKreissigISpandauUHHarderBInfectious and noninfectious endophthalmitis after intravitreal high-dosage triamcinolone acetonideAm J Ophthalmol2006141357958016490517
- JonasJBSpandauUHRenschFVon BaltzSSchlichtenbredeFInfectious and noninfectious endophthalmitis after intravitreal bevacizumabJ Ocul Pharmacol Ther200723324024217593007
- JonasJBSpandauUHSchlichtenbredeFShort-term complications of intravitreal injections of triamcinolone and bevacizumabEye200822459059118292795
- YamJCKwokAKUpdate of the management of postoperative endophthalmitisHong Kong Med J200410533734315479963
- ChhabraSKunimotoDYKaziLEndophthalmitis after open globe injury: microbiologic spectrum and susceptibilities of isolatesAm J Ophthalmol2006142585285417056367
- RecchiaFMBusbeeBGPearlmanRBCarvalho-RecchiaCAHoACChanging trends in the microbiologic aspects of postcataract endophthalmitisArch Ophthalmol2005123334134615767476
- MoshirfarMFeizVVitaleATWegelinJABasavanthappaSWolseyDHEndophthalmitis after uncomplicated cataract surgery with the use of fourth-generation fluoroquinolones: a retrospective observational case seriesOphthalmology2007114468669117184840
- OlsonRReducing the risk of postoperative endophthalmitisSurv Ophthalmol200449Suppl 2S55S6115028480
- KelkarAKelkarJAmuakuWKelkarUShaikhAHow to prevent endophthalmitis in cataract surgeriesIndian J Ophthalmol200856540340718711270
- Endophthalmitis Study GroupEuropean Society of Cataract and Refractive SurgeonsProphylaxis of postoperative endophthalmitis following cataract surgery: results of the ESCRS multicenter study and identification of risk factorsJ Cataract Refract Surg200733697898817531690
- MasketSPreventing, diagnosing, and treating endophthalmitisJ Cataract Refract Surg19982467257269642575
- SchmitzSDickHKrummenauerFPfeifferNEndophthalmitis in cataract surgery: results of a German surveyOphthalmology1999106101869187710519579
- JacksonWBlepharitis: current strategies for diagnosis and managementCan J Ophthalmol200843217017918347619
- GrodenLMurphyBRodniteJLid flora in blepharitisCornea19911050532019106
- RutarTZwickOMCockerhamKPHortonJCBilateral blindness from orbital cellulitis caused by community-acquired methicillin-resistant Staphylococcus aureusAm J Ophthalmol2005140474074216226533
- CannonPKeagDRadfordRAtaullahSLeatherbarrowBOur experience using primary oral antibiotics in the management of orbital cellulitis in a tertiary referral centreEye200923361261518309335
- DasJDekaAKuriGBhattacharjeeKDasDGogoiKBacteriology of chronic dacryocystitis in adult population of northeast IndiaOrbit200827424324718716961
- KubalAGaribaldiDDacryoadenitis caused by methicillin-resistant Staphylococcus aureusOphthal Plast Reconstr Surg20082415061
- BriscoeDRubowitzAAssiaEChanging bacterial isolates and antibiotic sensitivities of purulent dacryocystitisOrbit2005242959816191795
- HarbarthSSamoreMHAntimicrobial resistance determinants and future controlEmerg Infect Dis200511679480115963271
- GumsJGBoatwrightDWTottiNMartinezMAntimicrobial resistance in 11 hospitals in Puerto Rico: results of an antimicrobial resistance management (ARM) programP R Health Sci J200726318118918035809
- GoldsteinMHKowalskiRPGordonYJEmerging fluoroquinolone resistance in bacterial keratitis: a 5-year reviewOphthalmology199910671313131810406613
- MilianiKL’HeriteauFAlfandariSSpecific control measures for antibiotic prescription are related to lower consumption in hospitals: results from a French multicentre pilot studyJ Antimicrob Chemother200862482382918658196
- HobanDFelminghamDThe PROTEKT surveillance study: antimicrobial susceptibility of Haemophilus influenzae and Moraxella catarrhalis from community-acquired respiratory tract infectionsJ Antimicrob Chemother200250Suppl S1495912239228
- KirbyJTMutnickAHJonesRNBiedenbachDJPfallerMAGeographic variations in garenoxacin (BMS284756) activity tested against pathogens associated with skin and soft tissue infections: report from the SENTRY Antimicrobial Surveillance Program (2000)Diagn Microbiol Infect Dis200243430330912151191
- TenoverFCMechanisms of antimicrobial resistance in bacteriaAm J Med20061196 Suppl 1S3S10; discussion S62–S70.16735149
- BarlowGNathwaniDIs antibiotic resistance a problem? A practical guide for hospital cliniciansPostgrad Med J20058196168069216272230
- CroftACD’AntoniAVTerzulliSLUpdate on the antibacterial resistance crisisMed Sci Monit2007136RA103RA11817534243
- BrownSDRybakMJAntimicrobial susceptibility of Streptococcus pneumoniae, Streptococcus pyogenes and Haemophilus influenzae collected from patients across the USA, in 2001–2002, as part of the PROTEKT US studyJ Antimicrob Chemother200454Suppl 1i7i1515265831
- JacobsMRFelminghamDAppelbaumPCGrunebergRNThe Alexander Project 1998–2000: susceptibility of pathogens isolated from community-acquired respiratory tract infection to commonly used antimicrobial agentsJ Antimicrob Chemother200352222924612865398
- MarangonFBMillerDMuallemMSRomanoACAlfonsoECCiprofloxacin and levofloxacin resistance among methicillin-sensitive Staphylococcus aureus isolates from keratitis and conjunctivitisAm J Ophthalmol2004137345345815013867
- BlomquistPHMethicillin-resistant Staphylococcus aureus infections of the eye and orbit (an American Ophthalmological Society thesis)Trans Am Ophthalmol Soc200610432234517471350
- McDonaldMBBlondeauJMDeCoryHHMultidrug-resistant strains in clinical trials of besifloxacin in the treatment of bacterial conjunctivitisPresented at the American Academy of Ophthalmology Annual Meeting2008 Nov 8–11Atlanta, GA, USAPoster 070.
- BuznachNDaganRGreenbergDClinical and bacterial characteristics of acute bacterial conjunctivitis in children in the antibiotic resistance eraPediatr Infect Dis J200524982382816148850
- OhnsmanCRitterbandDO’BrienTGirgisDKabatAComparison of azithromycin and moxifloxacin against bacterial isolates causing conjunctivitisCurr Med Res Opin20072392241224917688706
- LichtensteinSJWagnerRSJamisonTBellBStromanDWSpeed of bacterial kill with a fluoroquinolone compared with nonfluoroquinolones: clinical implications and a review of kinetics of kill studiesAdv Ther20072451098111118029337
- ChalitaMRHofling-LimaALParanhosAJrSchorPBelfortRJrShifting trends in in vitro antibiotic susceptibilities for common ocular isolates during a period of 15 yearsAm J Ophthalmol20041371435114700643
- OliveiraADD’AzevedoPAFranciscoWIn vitro activity of fluoroquinolones against ocular bacterial isolates in Sao Paulo, BrazilCornea200726219419817251812
- AfshariNAMaJJDuncanSMTrends in resistance to ciprofloxacin, cefazolin, and gentamicin in the treatment of bacterial keratitisJ Ocul Pharmacol Ther200824221722318331204
- TuftSJMathesonMIn vitro antibiotic resistance in bacterial keratitis in LondonBr J Ophthalmol200084768769110873974
- ParmarPSalmanAKalavathyCMComparison of topical gatifloxacin 0.3% and ciprofloxacin 0.3% for the treatment of bacterial keratitisAm J Ophthalmol2006141228228616458681
- WilhelmusKRAbshireRLSchlechBAInfluence of fluoroquinolone susceptibility on the therapeutic response of fluoroquinolone-treated bacterial keratitisArch Ophthalmol200312191229123312963604
- MoshirfarMMirzaianGFeizVKangPCFourth-generation fluoroquinolone-resistant bacterial keratitis after refractive surgeryJ Cataract Refract Surg200632351551816631067
- MillerDFlynnPMScottIUAlfonsoECFlynnHWJrIn vitro fluoroquinolone resistance in staphylococcal endophthalmitis isolatesArch Ophthalmol2006124447948316606872
- AsbellPASahmDFLongitudinal nationwide antimicrobial susceptibility surveillance in ocular isolates: results from Ocular TRUST 2Presented at: American Society of Cataract and Refractive Surgery Annual Meeting2007 April 27–May 2San Diego, CA, USA
- MorrisseyIBurnettRViljoenLRobbinsMSurveillance of the susceptibility of ocular bacterial pathogens to the fluoroquinolone gatifloxacin and other antimicrobials in Europe during 2001/2002J Infect200449210911415236917
- BrownLResistance to ocular antibiotics: an overviewClin Exp Optom200790425826217535364
- TzepiIVergadosIKanellakopoulouKPharmacokinetics of intravenously administered moxifloxacin in eye compartments: an experimental studyInt J Antimicrob Agents200933216016218947985
- WiseRAndrewsJThe bactericidal activity of gatifloxacin in plasma and urineClin Microbiol Infect19984739239611864354
- DrusanoGLPharmacokinetics and pharmacodynamics of antimicrobialsClin Infect Dis200745Suppl 1S89S9517582578
- AmbrosePGBhavnaniSMRubinoCMPharmacokinetics-pharmacodynamics of antimicrobial therapy: it’s not just for mice anymoreClin Infect Dis2007441798617143821
- WrightDHBrownGHPetersonMLRotschaferJCApplication of fluoroquinolone pharmacodynamicsJ Antimicrob Chemother200046566968311062185
- FirsovAALubenkoIYVostrovSNPortnoyYAZinnerSHAntistaphylococcal effect related to the area under the curve/MIC ratio in an in vitro dynamic model: predicted breakpoints versus clinically achievable values for seven fluoroquinolonesAntimicrob Agents Chemother20054972642264715980331
- BlondeauJMZhaoXHansenGDrlicaKMutant prevention concentrations of fluoroquinolones for clinical isolates of Streptococcus pneumoniaeAntimicrob Agents Chemother200145243343811158737
- MetzlerKHansenGMHedlinPHardingEDrlicaKBlondeauJMComparison of minimal inhibitory and mutant prevention drug concentrations of 4 fluoroquinolones against clinical isolates of methicillin-susceptible and -resistant Staphylococcus aureusInt J Antimicrob Agents200424216116715288315
- DrusanoGLLouieADezielMGumboTThe crisis of resistance: identifying drug exposures to suppress amplification of resistant mutant subpopulationsClin Infect Dis200642452553216421797
- TamVHLouieAFritscheTRImpact of drug-exposure intensity and duration of therapy on the emergence of Staphylococcus aureus resistance to a quinolone antimicrobialJ Infect Dis2007195121818182717492598
- RobertsonSMCurtisMASchlechBAOcular pharmacokinetics of moxifloxacin after topical treatment of animals and humansSurv Ophthalmol200550Suppl 1S32S4516257309
- Quixin [package insert]Jacksonville, FLVistakon Pharmaceuticals LLC42006
- BlondeauJMFluoroquinolones: mechanism of action, classification, and development of resistanceSurv Ophthalmol200449Suppl 2S73S7815028482
- WardKWLepageJFDriotJYNonclinical pharmacodynamics, phar-macokinetics, and safety of BOL-303224-A, a novel fluoroquinolone antimicrobial agent for topical ophthalmic useJ Ocul Pharmacol Ther200723324325617593008
- CambauEMatratSPanXSTarget specificity of the fluoroquinolone besifloxacin in Streptococcus pneumoniae, Staphylococcus aureus and Escherichia coliJ Antimicrob Chemother200963344345019147516
- BrunnerLSNortonSEBlondeauJMIn vitro activity of SS734, a novel fluoroquinolone, against pathogens associated with bacterial conjunctivitis[poster] 17th European Congress of Clinical Microbiology and Infectious DiseasesMarch 31–April 3, 2007Munich, GermanyPoster P1679.
- ProkschJWDriotJYWardKWNonclinical ocular and systemic pharmacokinetics of BOL-303224-A, a novel fluoroquinolone antimicrobial agent for topical ophthalmic usePresented at the Association for Research in Vision and Ophthalmology Annual Meeting2007 Apr 27–May 1Fort Lauderdale, FL, USAPoster #B654.
- ChappaAKProkschJWWardKWComparison of the ocular and systemic pharmacokinetics of besifloxacin, a novel fluoroquinolone antibiotic, with moxifloxacin and gatifloxacin in pigmented rabbitsPresented at the Association for Research in Vision and Ophthalmology Annual Meeting2008 Apr 27–May 1Fort Lauderdale, FL, USAPoster #D684.
- ZhangJZCavetMEWardKWAnti-inflammatory effects of besifloxacin, a novel fluoroquinolone, in primary human corneal epithelial cellsCurr Eye Res2008331192393319085374
- ZhangJZWardKWBesifloxacin, a novel fluoroquinolone antimicrobial agent, exhibits potent inhibition of pro-inflammatory cytokines in human THP-1 monocytesJ Antimicrob Chemother200861111111617965029
- GranvilCPSiou-MermetRComstockTJonasseMProkschJWOcular pharmacokinetics of besifloxacin, a novel fluoroquinolone antimicrobial agent for topical ophthalmic use, in healthy volunteersPresented at the Association for Research in Vision and Ophthalmology Annual Meeting2008 Apr 27–May 1Fort Lauderdale, FL, USAPoster #D691.
- ProkschJGranvilCPSiou-MermetRComstockTPaternoMWardKWOcular pharmacokinetics of besifloxacin following topical administration to rabbits, monkeys, and humansJ Ocul Pharm Ther2009254335341
- LiuZLiJNieSLiuHDingPPanWStudy of an alginate/HPMC-based in situ gelling ophthalmic delivery system for gatifloxacinInt J Pharm20063151–2121716616442
- MansourMMansourSMortadaNDAbd ElhadySSOcular poloxamer-based ciprofloxacin hydrochloride in situ forming gelsDrug Dev Ind Pharm200834774475218612913
- AbrahamSFurtadoSBharathSBasavarajBVDeveswaranRMadhavanVSustained ophthalmic delivery of ofloxacin from an ion-activated in situ gelling systemPak J Pharm Sci200922217517919339228
- KarpeckiPDePaolisMHunterJABesifloxacin ophthalmic suspension 0.6% in patients with bacterial conjunctivitis: a multicenter, prospective, randomized, double-masked, vehicle-controlled, 5-day efficacy and safety studyClin Ther200931351452619393842
- TepedinoMEHellerWHUsnerDWPhase III efficacy and safety study of besifloxacin ophthalmic suspension 0.6% in the treatment of bacterial conjunctivitisCurr Med Res Opin20092551159116919323612
- McDonaldMBProtzkoEEBrunnerLSEfficacy and safety of besifloxacin ophthalmic suspension 0.6% compared with moxifloxacin ophthalmic solution 0.5% for treating bacterial conjunctivitisOphthalmology200911691615162319643483
- Antibiotic/Antimicrobial Resistance: Clinical guidelinesAvailable at: http://www.cdc.gov/DRUGRESISTANCE/clinical.htm Accessed Dec. 5, 2008.
- World Health Organization Antimicrobial resistance. Available at: http://www.who.int/mediacentre/factsheets/fs194/en/print.html 2002 Fact sheet 194 Accessed Dec. 5, 2008.
- YoneyamaHKatsumataRAntibiotic resistance in bacteria and its future for novel antibiotic developmentBiosci Biotechnol Biochem20067051060107516717405